For research use only. Not for use in humans.

Briakinumab (Anti-IL-12) (IL-12a & IL-12b)

Cat.No.A2947 Purity:99%

Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human Interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.

Quality Control

Batch: A294701 Purity: 99% Protein concentration: 6.182mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human Interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25989338/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	339308-60-0
Molecular Weight	143.86
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.